Dr. Barrio on Treatment Options for HER2+ Breast Cancer

Video

In Partnership With:

Andrea V. Barrio, MD, FACS, breast surgical oncologist, Memorial Sloan Kettering Cancer Center, discusses treatment options for patients with HER2-positive breast cancer.

Andrea V. Barrio, MD, FACS, breast surgical oncologist, Memorial Sloan Kettering Cancer Center, discusses treatment options for patients with HER2-positive breast cancer.

HER2-positive disease is a subtype of breast cancer that represents about 20% of breast cancer cases, Barrio says. In 2006, adjuvant targeted therapy with trastuzumab (Herceptin) became widely used. More recently, dual HER2-targeted therapy with trastuzumab and pertuzumab (Perjeta) has shaped the landscape. The challenge remaining with this disease is determining which patients should undergo upfront surgery or neoadjuvant therapy. Barrio notes that this should depend on physician and patient goals, although it appears that surgery is becoming de-escalated in the paradigm in order to maintain patient quality of life.

For example, the goal of frontline chemotherapy for patients with node-positive disease is to make them node-negative, leading to less surgery. The biggest advantage of HER2-positive breast cancer is its high response rate to systemic therapy.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD